WOOJUNG BIO, Inc. Logo

WOOJUNG BIO, Inc.

Offers pre-clinical CRO services, research facility engineering, and startup incubation.

215380 | KO

Overview

Corporate Details

ISIN(s):
KR7215380007
LEI:
Country:
South Korea
Address:
경기도 화성시 동탄기흥로 593-8 (영천동, 우정바이오 신약클러스터I), 화성시

Description

WOOJUNG BIO, Inc. is a bio-infrastructure company providing an integrated platform for research and development in the life sciences. The company's core activities are structured around three main pillars. First, it offers comprehensive pre-clinical Contract Research Organization (CRO) services, including efficacy studies, safety evaluations, and pharmaceutical analysis, utilizing its advanced animal laboratory facilities. Second, it specializes in the engineering and construction of modernized research environments, offering complete solutions for building and managing smart laboratories, animal rooms, and GMP-compliant clean rooms. Third, through its 'WOOJUNG BIO Cluster' open innovation platform, it provides R&D infrastructure, incubation, and acceleration support for bio-ventures and startups, aiming to foster the new drug development ecosystem and help transform innovative ideas into therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2019-11-14 00:00
분기보고서 (2019.09)
Korean 995.2 KB
2019-11-14 00:00
조회공시요구(현저한시황변동)에대한답변(중요정보없음)
Korean 5.0 KB
2019-11-14 00:00
신주인수권행사(제4회차)
Korean 13.5 KB
2019-11-13 00:00
조회공시요구(현저한시황변동)
Korean 3.6 KB
2019-11-11 00:00
전환가액의조정(제5회차)
Korean 13.4 KB
2019-11-11 00:00
신주인수권행사가액의조정(제4회차)
Korean 14.0 KB
2019-09-27 00:00
주식등의대량보유상황보고서(일반)
Korean 107.4 KB
2019-09-26 00:00
[첨부추가]주요사항보고서(유형자산양수결정)
Korean 12.9 KB
2019-09-16 00:00
주식등의대량보유상황보고서(일반)
Korean 109.6 KB
2019-08-16 00:00
주식등의대량보유상황보고서(일반)
Korean 109.9 KB
2019-08-14 00:00
반기보고서 (2019.06)
Korean 980.0 KB
2019-08-14 00:00
파생상품거래손실발생
Korean 12.2 KB
2019-08-13 00:00
주식등의대량보유상황보고서(약식)
Korean 58.0 KB
2019-08-12 00:00
전환가액의조정(제5회차)
Korean 12.9 KB
2019-08-12 00:00
신주인수권행사가액의조정(제4회차)
Korean 13.5 KB

Automate Your Workflow. Get a real-time feed of all WOOJUNG BIO, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for WOOJUNG BIO, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for WOOJUNG BIO, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.